{"id":"W2947290320","doi":"10.1634/theoncologist.2019-0027","title":"Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; University of Toronto; University Health Network; Royal Victoria Hospital; University of Alberta; Royal Victoria Regional Health Centre; Juravinski Cancer Centre; Montreal General Hospital; McMaster University; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Pembrolizumab; Medicine; Atezolizumab; Oncology; Lung cancer; Internal medicine; Nivolumab; Bevacizumab; Pemetrexed; Anaplastic lymphoma kinase; Chemotherapy; Ipilimumab; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004479096,0.0001549798,0.0003259356,0.00008014806,0.00009711964,0.00002147008,0.0001756842,0.0001057693,0.0004388991],"category_scores_gemma":[0.00003455734,0.00009716894,0.0001293334,0.0002701901,0.0001101033,0.00004034645,0.0000652258,0.0002843183,0.00006248389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006068656,"about_ca_system_score_gemma":0.0002143736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002545775,"about_ca_topic_score_gemma":0.003459476,"domain_scores_codex":[0.9989904,0.00003624606,0.0003363287,0.0002155318,0.0001527302,0.0002688053],"domain_scores_gemma":[0.9992113,0.0001954466,0.0001331193,0.0003622878,0.00005176353,0.00004615737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001161257,0.001161782,0.9651487,0.0004578355,0.0001617797,0.00003072537,0.002253945,0.0002985728,0.01980364,0.0000843875,0.00432373,0.005113634],"study_design_scores_gemma":[0.01829404,0.0008263615,0.9397931,0.0005640718,0.0001547933,0.00001375326,0.001156213,0.001929993,0.007541509,0.00008711338,0.02925852,0.0003805397],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.975667,0.0009138962,0.00006839034,0.01212347,0.0007327239,0.0011476,0.00001242487,0.00004591909,0.009288603],"genre_scores_gemma":[0.9903433,0.0004595709,0.0001264507,0.001992748,0.0001036062,0.0001553197,0.00001310467,0.00002089651,0.006785032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02535563,"threshold_uncertainty_score":0.4805638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02960947122563826,"score_gpt":0.3227680076414282,"score_spread":0.2931585364157899,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}